Dr. Sean Esmonde

Consultants

Profile

Dr. Sean Esmonde is a consultant cardiologist specialising in electrophysiology (rhythm abnormalities) and cardiac devices.

He completed his cardiology specialty training in Northern Ireland. Dr. Esmonde initially completed his degree and initial medical training in Manchester, England.

Following this, Dr. Esmonde gained a fellowship sub-specialising in electrophysiology and cardio-genetics in Mater Misercordiae University Hospital, Dublin. Here, he worked in the Family Heart Screening Clinic before taking up a consultant post in Dublin. He would later move to a permanent consultant post in the Belfast Health and Social Care Trust.

Dr. Esmonde investigates general cardiac and rhythm disorders, and provide solutions in a compassionate and personalised manner. He performs procedures in the Belfast Health and Social Care Trust.

As a consultant cardiologist, he is dedicated to providing the highest standard of care to his patients, utilising a patient-centered approach that emphasises empathy, communication, and shared decision-making. Dr. Esmonde believes in staying at the forefront of medical advancements through continued education, research, and collaboration with colleagues, ultimately striving to improve outcomes and quality of life for individuals with cardiovascular diseases.

Current NHS/HSE Posts

Belfast Health and Social Care Trust – Substantive Consultant Cardiologist in Electrophysiology

Mater Misericordiae University Hospital - Locum Consultant Cardiologist in Electrophysiology and Cardiogenetics

Qualifications

MBChB (with Distinction), University of Manchester, 2012

Additional Training – Mater Misericordiae University Hospital, Dublin, 2022

Professional bodies (Positions held in last 3 years)

Member of the Royal College of Physicians

Member of British Heart Rhythm Society

Member of European Society of Cardiology

Publications

Esmonde S, McCullagh D, Kelly B, McCann C. SGLT2 Inhibitors – Something in the water, or the heart of the matter? Ulster Med J. 2020;89(2):113.

Esmonde S, Soong C-N, Kerr B, et al. P970 How does pace and ablate for poorly controlled atrial fibrillation affect heart failure metrics? EP Europace, Volume 22, Issue Supplement 1, June 2020, euaa162.060.

Piqueras-Flores J, Villacorta-Argüelles E, Galvin J, Climent-Payá V, Escobar-López LE, Amor-Salamanca A, Garcia-Hernandez S, Esmonde S, Martínez-Del Río J, Soto-Pérez M, Garcia-Pavia P, Ochoa JP. Intermediate-effect size p.Arg637Gln in FHOD3 increases risk of HCM and is associated with an aggressive phenotype in homozygous carriers. J Med Genet. 2023 Dec 30:jmg-2023-109413.

Peer reviewer for journal – Cardiovascular Diagnostics and Therapeutics

Member of European Society of Cardiology working group on European Exam in Core Cardiology - Rhythm Disorders, 2022-present

Treatment Areas

Treatments and areas of interest

Symptoms – palpitations, loss of consciousness/blackouts, breathlessness, reduced exercise capacity, irregular heartbeat
Investigations – abnormal ECGs, holter monitors, treadmill tests, echocardiogram
Conditions – atrial fibrillation (AF), atrial flutter, supraventricular and ventricular tachycardia (SVT and VT), cardiomyopathy, channelopathy, sudden cardiac death survivors
Cardiac devices – pacemakers, ICDs
Procedures – electrophysiology studies and ablations, cardiac device implantation (pacemakers, loop recorders, ICDs)